Cyclacel Pharmaceuticals ...
0.37
-0.02 (-4.64%)
At close: Jan 15, 2025, 11:47 AM
undefined%
Bid 0.37
Market Cap 4.16M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -27.4
PE Ratio (ttm) -0.01
Forward PE n/a
Analyst Buy
Ask 0.38
Volume 172,196
Avg. Volume (20D) 3,691,852
Open 0.37
Previous Close 0.39
Day's Range 0.36 - 0.38
52-Week Range 0.31 - 4.00
Beta undefined

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 2004
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CYCC

Analyst Forecast

According to 1 analyst ratings, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 2872.97% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Cyclacel Pharmaceuticals Inc. is scheduled to release its earnings on Mar 18, 2025, during market hours.
Analysts project revenue of $10.00K, reflecting a -67.74% YoY shrinking and earnings per share of -0.29, making a -95.35% decrease YoY.
1 week ago · Source
+24.02%
Cyclacel Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
2 months ago · Source
+9.76%
Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.